To summarize, for the first time, with the present work, we aim at characterizing cortical MS on the AD continuum by developing MSNs relying on both macro- and microscopic features of the brain tissue of individuals from the pre-clinical to the MCI stage, categorized as Aβ-positive/tau-positive (Aβ+/tau+) and Aβ-negative/tau-negative (Aβ−/tau−). The gene discussed is MAPT; the disease is Alzheimer disease.